Notes
2017 US dollars
Reference
Zhang TT, et al. Cost-effectiveness of Daratumumab-based Triplet Therapies in Patients With Relapsed or Refractory Multiple Myeloma. Clinical Therapeutics : 10 Jul 2018. Available from: URL: http://doi.org/10.1016/j.clinthera.2018.05.012
Rights and permissions
About this article
Cite this article
Daratumunab too costly to be cost effective in USA. PharmacoEcon Outcomes News 808, 15 (2018). https://doi.org/10.1007/s40274-018-5130-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-5130-9